AlloVir News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.01.24	EQS-News: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages AlloVir, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
29.01.24	EQS-News: ROSEN, A LEADING LAW FIRM, Encourages AlloVir, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
28.01.24	EQS-News: ROSEN, SKILLED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
27.01.24	EQS-News: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
27.01.24	EQS-News: ROSEN, A RANKED AND LEADING FIRM, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
26.01.24	EQS-News: ROSEN, NATIONAL TRIAL LAWYERS, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
24.01.24	EQS-News: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages AlloVir, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALVR (EQS Group)
22.12.23	Why Is Penny Stock Cell Therapy Focused AlloVir Stock Plummeting Today? (Benzinga)
16.11.23	AlloVir to Present at the Piper Sandler 35th Annual Healthcare Conference (Businesswire)
02.11.23	AlloVir Reports Third Quarter 2023 Financial Results (Businesswire)
28.08.23	AlloVir to Present at Upcoming Investor Conferences (Businesswire)
03.08.23	AlloVir Reports Second Quarter 2023 Financial Results (Businesswire)
22.06.23	AlloVir Prices Public Offering (RTTNews)
22.06.23	Pre-market Movers: PIXY, ROOT, CDMO, ALVR, KWE… (RTTNews)
22.06.23	AlloVir Announces Pricing of Public Offering of Common Stock (Businesswire)
21.06.23	AlloVir Announces Proposed Public Offering of Common Stock (Businesswire)
16.05.23	AlloVir Announces Appointment of Cintia Piccina, PharmD, MBA, as Chief Commercial Officer (Businesswire)
04.05.23	AlloVir Reports First Quarter 2023 Financial Results (Businesswire)
01.05.23	AlloVir to Present at the BofA Securities 2023 Health Care Conference (Businesswire)
26.04.23	AlloVir Announces Positive Results Including Long-Term Mortality Data in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at EBMT 2023 (Businesswire)
23.02.23	AlloVir Appoints Derek Adams, Ph.D., to Board of Directors (Businesswire)
15.02.23	AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook (Businesswire)
15.02.23	AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia (Businesswire)
06.05.21	AlloVir Reports First Quarter 2021 Financial Results (Businesswire)
22.03.21	AlloVir Appoints Diana M. Brainard, M.D., as Chief Executive Officer, Effective May 17, 2021 (Businesswire)
17.02.21	AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference (Businesswire)
11.02.21	AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience (Businesswire)
11.02.21	AlloVir Reports Full Year 2020 Financial Results (Businesswire)
17.12.20	AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Multi-Virus Specific T Cell Therapy Targeting Four Devastating Respiratory Viruses (Businesswire)
07.12.20	Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at the 62nd American Society of Hematology Annual Meeting (Businesswire)
05.12.20	Preclinical Data Demonstrate Anti-Viral Activity of AlloVir’s ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

CieFinRichemont	121.20	2.24 %	K V
Swiss Re	129.80	1.17 %	K V
Lonza Grp	526.00	0.88 %	K V
Logitech Intl	71.52	0.70 %	K V
UBS Group	28.44	0.49 %	K V
Kuehne+Nagel Int	208.00	-0.72 %	K V
Swiss Life Hldg	727.20	-0.87 %	K V
Givaudan	3’885.00	-1.22 %	K V
Novartis	92.32	-1.45 %	K V
Sonova Hldg	306.70	-1.73 %	K V

Nachrichten zu AlloVir Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten